Efektivitas Immunoterapi Dalam Tatalaksana Guillain-Barré Syndrome Pada Anak
DOI:
https://doi.org/10.36452/jkdoktmeditek.v25i3.1783Keywords:
Autoimmune, GBS, Immunoglobulin, Immunotherapy, Peripheral Nervous SystemAbstract
Guillain-Barré Syndrome (GBS) is an immune-mediated inflammatory disorder of the peripheral nervous system in which an autoimmune response is directed against peripheral nerves. The pathogenesis of GBS is believed to be an abnormal immune response to an antecedent event, most commonly an infection, and in a few cases associated with vaccination especially in children. The clinical manifestation of GBS is rapid and ascending progressive bilateral limb weakness. Therapies which are still being used and considered effective are intravenous immunoglobulin and plasmapheresis. New modalities such as Interferon-β (IFN-β), Cyclophosphamide, and Human Monoclonal Antibody still require further study related to the effectiveness and potential side effects. The prognosis of GBS in children is much better, the mortality rate is also very low, affecting 1-2% of children with GBS, while only 4% of paediatric patients are in need of respiratory support during hospitalisation.
References
1. Gopalakrishna KN, Ramesh VJ. Management of Guillain-Barré Syndrome. J Neuroanaesthesiol Crit Care. 2019;6:160-6. doi:10.1055/s-0039-1688896.
2. Rosen BA. Guillain-Barré Syndrome. Pediatrics in Review. 2012;33(4):164-70. doi:10.1542/pir.33-4-164.
1. Gopalakrishna KN, Ramesh VJ. Management of guillain-barré syndrome. J Neuroanaesthesiol Crit Care. 2019;6:160-6. doi:10.1055/s-0039-1688896.
2. Rosen BA. Guillain-Barré syndrome. Pediatrics in Review. 2012;33(4):164-70. doi:10.1542/pir.33-4-164.
3. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijddicks EF. Anticipating mechanical ventilation in guillain-barré syndrome. Arch Neurol. 2001;58(6):893-8. doi:10.1001/archneur.58.6.893.
4. Berg BV, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469-82. doi: 10.1038/nrneurol.2014.121.
5. Yuki N, Hartung HP. Guillain–Barré syndrome. N Engl J Med. 2012;366:2294–304. doi: 10.1056/NEJMra1114525.
6. Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O’Brien SJ. Incidence of Guillain–Barré syndrome among patients with campylobacter infection: a general practice research database study. J Infect Dis. 2006;194:95–7. doi: 10.1086/504294.
7. Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723–31. doi: 10.1038/nrneurol.2016.172.
8. Willison HJ, Jacobs BC, Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388:717-27. doi: 10.1016/S0140-6736(16)00339-1.
9. Fokke C, Berg BV, Drenthen J, Walgaard C, Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of brighton criteria. Brain. 2014;137:33-43.doi:10.1093/brain/awt285.
10. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barre Syndrome and fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599-612.
11. Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barré syndrome. Arch Dis Child Educ Pract Ed. 2007;92(6):161-8. doi:10.1136/adc.2004.065706.
12. Lukito V, Mangunatmadja I, Pudjiadi AH, Puspandjono TM. Plasmaferesis sebagai terapi sindrom Guillain Barré berat pada anak. Sari Pediatri. 2010;11(6):450-1. doi: 10.14238/sp11.6.2010.448-55.
13. Alboudi AM, Sarathchandran P, Geblawi SS, Kayed DM, Inshasi J, Purayil SP, et al. Rescue treatment in patients with poorly responsive Guillain-Barré Syndrome. Sage Open Medicine. 2019;(7):1-5. doi: 10.1177/2050312119840195.
14. Verboon C, Doom PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2016;88(4):346-52. doi:10.1136/jnnp-2016-314862.
15. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116(1):8-14. doi: 10.1542/peds.2004-1324.
16. El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain-Barré syndrome: a randomized study. Crit Care. 2011;15(4):R164. doi:10.1186/cc10305.
17. Kamate M, Detroja M, Reddy AN. Do all children with Guillain-Barre syndrome need immunotherapy? The Indian J of Ped. 2019. Doi: 10.1007/s12098-019-02864-0
18. Ortiz-Corredor F, Pena Preciado M. Use of immunoglobulin in severe childhood Guillain-Barre syndrome. Acta Neurol Scand. 2007;115:289-93. doi: 10.1111/j.1600-0404.2006.00766.x
19. Restrepo-Jimenez P, Rodríguez Y, González P, Chang C, Gershwin ME, Anaya JM. The immunotherapy of Guillain-Barré syndrome. Expert Opin Biol Ther. 2018;18(6):619-31. doi: 10.1080/14712598.2018.1468885.
20. Xiao J, Simard AR, Shi FD, Hao J. New strategies in the management of Guillain Barré syndrome. Clin Rev Allergy Immunol. 2014;47(3):274-88. doi: 10.1007/s12016-013-8388-5.
21. Lee JH, Sung IY, Rew IS. Clinical Presentation and prognosis of childhood Guillain Barre syndrome. J of Paed and Chil Health. 2008;44:449-54. doi : 10.1111/j.1440-1754.2008.01325.x
22. Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain Barré syndrome: a prospective multicentre study. Neuropediatrics. 2007;38(1):10-7. doi:10.1055/s-2007-981686
23. Vajsar J, Fehlings D, Stephens D. Longterm outcome in children with Guillain Barré syndrome. J Pediatr. 2003;142(3):305-9. doi: 10.1067/mpd.2003.115.
2. Rosen BA. Guillain-Barré Syndrome. Pediatrics in Review. 2012;33(4):164-70. doi:10.1542/pir.33-4-164.
1. Gopalakrishna KN, Ramesh VJ. Management of guillain-barré syndrome. J Neuroanaesthesiol Crit Care. 2019;6:160-6. doi:10.1055/s-0039-1688896.
2. Rosen BA. Guillain-Barré syndrome. Pediatrics in Review. 2012;33(4):164-70. doi:10.1542/pir.33-4-164.
3. Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijddicks EF. Anticipating mechanical ventilation in guillain-barré syndrome. Arch Neurol. 2001;58(6):893-8. doi:10.1001/archneur.58.6.893.
4. Berg BV, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10:469-82. doi: 10.1038/nrneurol.2014.121.
5. Yuki N, Hartung HP. Guillain–Barré syndrome. N Engl J Med. 2012;366:2294–304. doi: 10.1056/NEJMra1114525.
6. Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O’Brien SJ. Incidence of Guillain–Barré syndrome among patients with campylobacter infection: a general practice research database study. J Infect Dis. 2006;194:95–7. doi: 10.1086/504294.
7. Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress. Nat Rev Neurol. 2016;12(12):723–31. doi: 10.1038/nrneurol.2016.172.
8. Willison HJ, Jacobs BC, Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388:717-27. doi: 10.1016/S0140-6736(16)00339-1.
9. Fokke C, Berg BV, Drenthen J, Walgaard C, Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of brighton criteria. Brain. 2014;137:33-43.doi:10.1093/brain/awt285.
10. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, Baxter R, et al. Guillain-Barre Syndrome and fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29:599-612.
11. Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barré syndrome. Arch Dis Child Educ Pract Ed. 2007;92(6):161-8. doi:10.1136/adc.2004.065706.
12. Lukito V, Mangunatmadja I, Pudjiadi AH, Puspandjono TM. Plasmaferesis sebagai terapi sindrom Guillain Barré berat pada anak. Sari Pediatri. 2010;11(6):450-1. doi: 10.14238/sp11.6.2010.448-55.
13. Alboudi AM, Sarathchandran P, Geblawi SS, Kayed DM, Inshasi J, Purayil SP, et al. Rescue treatment in patients with poorly responsive Guillain-Barré Syndrome. Sage Open Medicine. 2019;(7):1-5. doi: 10.1177/2050312119840195.
14. Verboon C, Doom PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2016;88(4):346-52. doi:10.1136/jnnp-2016-314862.
15. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116(1):8-14. doi: 10.1542/peds.2004-1324.
16. El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain-Barré syndrome: a randomized study. Crit Care. 2011;15(4):R164. doi:10.1186/cc10305.
17. Kamate M, Detroja M, Reddy AN. Do all children with Guillain-Barre syndrome need immunotherapy? The Indian J of Ped. 2019. Doi: 10.1007/s12098-019-02864-0
18. Ortiz-Corredor F, Pena Preciado M. Use of immunoglobulin in severe childhood Guillain-Barre syndrome. Acta Neurol Scand. 2007;115:289-93. doi: 10.1111/j.1600-0404.2006.00766.x
19. Restrepo-Jimenez P, Rodríguez Y, González P, Chang C, Gershwin ME, Anaya JM. The immunotherapy of Guillain-Barré syndrome. Expert Opin Biol Ther. 2018;18(6):619-31. doi: 10.1080/14712598.2018.1468885.
20. Xiao J, Simard AR, Shi FD, Hao J. New strategies in the management of Guillain Barré syndrome. Clin Rev Allergy Immunol. 2014;47(3):274-88. doi: 10.1007/s12016-013-8388-5.
21. Lee JH, Sung IY, Rew IS. Clinical Presentation and prognosis of childhood Guillain Barre syndrome. J of Paed and Chil Health. 2008;44:449-54. doi : 10.1111/j.1440-1754.2008.01325.x
22. Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain Barré syndrome: a prospective multicentre study. Neuropediatrics. 2007;38(1):10-7. doi:10.1055/s-2007-981686
23. Vajsar J, Fehlings D, Stephens D. Longterm outcome in children with Guillain Barré syndrome. J Pediatr. 2003;142(3):305-9. doi: 10.1067/mpd.2003.115.
Downloads
Published
2019-12-23
How to Cite
Reynaldo, G., & Desiree, A. (2019). Efektivitas Immunoterapi Dalam Tatalaksana Guillain-Barré Syndrome Pada Anak. Jurnal Kedokteran Meditek, 25(3), 107–114. https://doi.org/10.36452/jkdoktmeditek.v25i3.1783
Issue
Section
Tinjauan Pustaka
